Hyperbaric Oxygen Therapy (HBOT) is a painless and specialised oxygen therapy that involves breathing pure oxygen whilst in a hyperbaric chamber at increased atmospheric pressure (higher than normal air pressure). This allows blood plasma to absorb up to ten to fifteen times more oxygen at pressures greater than sea level.
FDA Approved Conditions
As of July 2021, the FDA has authorised hyperbaric chambers for the following disorders:
*** Please note that the Undersea and Hyperbaric Medical Society and The European Undersea and Baromedical Society have another list, so the approved conditions may differ slightly.
*Please note that we regretfully cannot offer service to patients with open wounds at NUMA. We advise patients with problem wounds to contact London Hyperbaric Medicine (LHM Healthcare Group), operating at both Whipps Cross University Hospital (Barts Health Trust) and James Paget University Hospital.
Hyperbaric oxygen therapy is an emerging therapy, and so research into its efficacy is ongoing. HBOT is being studied for the conditions listed below, including COVID-19. However, at this time, neither the FDA nor NICE has cleared or authorised the use of any HBOT to treat COVID-19 or any emerging conditions beyond those listed above. The website, clinicaltrials.gov, has more information on HBOT clinical trials for COVID-19 and other conditions.
Call or Contact us via our webform for more information or to discuss your initial consultation.
Meet our medical consultant for a face to face assessment & examination to find out if HBOT is suitable for you.
Receive a tailored management plan especially for you, based on the latest medical research.
Begin your treatment overseen by our trained hyperbaric oxygen chamber operator.